Lucid Diagnostics Inc (LUCD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lucid Diagnostics Inc (LUCD) has a cash flow conversion efficiency ratio of -1.150x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.58 Million) by net assets ($10.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Lucid Diagnostics Inc balance sheet quality to measure how much of total assets are equity-financed.
Lucid Diagnostics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Lucid Diagnostics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore LUCD debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Lucid Diagnostics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lucid Diagnostics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Walchandnagar Industries Limited
NSE:WALCHANNAG
|
0.035x |
|
Smartbroker Holding AG
XETRA:SB1
|
-0.051x |
|
Seven Hills Realty Trust
NASDAQ:SEVN
|
0.015x |
|
HomesToLife Ltd
NASDAQ:HTLM
|
0.084x |
|
Kumho Electric
KO:001210
|
0.274x |
|
Cheffelo AB
ST:CHEF
|
0.097x |
|
MEDICLIN Aktiengesellschaft
XETRA:MED
|
0.097x |
|
KABE Group AB (publ.)
ST:KABE-B
|
0.078x |
Annual Cash Flow Conversion Efficiency for Lucid Diagnostics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Lucid Diagnostics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Lucid Diagnostics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.94 Million | $-46.48 Billion | -4250.640x | -51814.82% |
| 2024-12-31 | $5.39 Million | $-44.14 Million | -8.188x | -157.66% |
| 2023-12-31 | $-2.31 Million | $-32.82 Million | 14.200x | +1202.49% |
| 2022-12-31 | $23.05 Million | $-29.68 Million | -1.288x | -299.05% |
| 2021-12-31 | $54.74 Million | $-17.67 Million | -0.323x | -177.52% |
| 2020-12-31 | $-13.52 Million | $-5.63 Million | 0.416x | -6.38% |
| 2019-12-31 | $-5.31 Million | $-2.36 Million | 0.445x | +315.70% |
| 2018-12-31 | $-1.06 Million | $-113.70K | 0.107x | -- |
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with th… Read more